Summary
Boston Scientific Corporation reported strong revenue growth for the third quarter and first nine months of 2022, with net sales reaching $3.17 billion and $9.44 billion, respectively. This represents an increase of 8.1% and 7.7% compared to the prior year periods, driven by organic growth and recent strategic acquisitions, despite a negative impact from foreign currency fluctuations. The company's net income available to common stockholders for the third quarter was $174 million ($0.12 per diluted share). On an adjusted basis, excluding certain charges and credits, the net income was $620 million ($0.43 per diluted share). For the first nine months, reported net income available to common stockholders was $516 million ($0.36 per diluted share), with adjusted net income at $1.816 billion ($1.26 per diluted share). The company highlighted operational execution and the strength of its diverse product portfolio as key drivers for its performance. Key financial events during the period included significant investments in acquisitions, such as Baylis Medical, and continued focus on research and development to fuel future growth. The company also managed its debt effectively, refinancing a portion of its outstanding notes and maintaining compliance with its financial covenants.
Financial Highlights
49 data points| Revenue | $3.17B |
| Cost of Revenue | $979.00M |
| Gross Profit | $2.19B |
| SG&A Expenses | $1.13B |
| Operating Expenses | $1.83B |
| Operating Income | $358.00M |
| Interest Expense | $63.00M |
| Net Income | $188.00M |
| EPS (Basic) | $0.12 |
| EPS (Diluted) | $0.12 |
| Shares Outstanding (Basic) | 1.43B |
| Shares Outstanding (Diluted) | 1.44B |
Key Highlights
- 1Net sales increased by 8.1% to $3.17 billion in Q3 2022 and by 7.7% to $9.44 billion for the first nine months of 2022, driven by operational growth and acquisitions.
- 2Reported net income available to common stockholders was $174 million ($0.12 EPS) for Q3 2022 and $516 million ($0.36 EPS) for the first nine months of 2022.
- 3Adjusted net income available to common stockholders was $620 million ($0.43 EPS) for Q3 2022 and $1.816 billion ($1.26 EPS) for the first nine months of 2022, demonstrating strong underlying profitability.
- 4The company completed the acquisition of Baylis Medical Company Inc. in Q1 2022, significantly expanding its electrophysiology and structural heart portfolios.
- 5Gross profit margin remained strong at 69.1% for Q3 2022, though slightly down from 69.3% in the prior year, impacted by inflation but offset by higher-margin products.
- 6Research and development expenses increased by 9% in Q3 and 12% in the first nine months, reflecting continued investment in innovation.
- 7The company maintained compliance with its financial covenants, with a reported leverage ratio of 2.50 times as of September 30, 2022, well below the maximum permitted 3.75 times.